Boundless Bio
- Founded: 2019
- Location: La Jolla, CA
- Employee range: 50 - 200
- Clinical stage: Clin1
- Therapy area: Oncology
- Drug types: ONC
- Lead product: BBI-355
- Product link: https://boundlessbio.com/what-we-do/
- Funding: $100M C May 2023; $105M B Apr 2021; $46M Sep 2019
- Investors: ARCH Venture Partners, City Hill, Leaps by Bayer, RA Capital, Nextech Invest, Fidelity Management & Research Company LLC, Redmile Group, Wellington Management, Surveyor Capital (a Citadel company), PFM Health Sciences, Logos Capital, Vertex Ventures HC, GT Healthcare Capital Partners, Boxer Capital of Tavistock Group, Alexandria Venture Investments
boundlessbio.com linkedin.com job board
Short description:
Cancer Treatments targeting extra-chromosomal DNA
Drug notes:
BBI-825 Clin0 oncology; EcHo Clin0 oncology diagnostic; 2 programs RD oncology
Long description:
Boundless Bio is developing therapeutics directed against extrachromosomal DNA (eDNA) to treat the most intractable cancers. ecDNAs are large units of circular DNA that reside within the cell nucleus yet are distinct from the chromosomal DNA. As ecDNAs can encode genes, they provide a mechanism for higher copy numbers of oncogenes, genes that are known to drive aggressive tumor growth and resistance to cancer treatments. Boundless has identified ecDNA as a differentiating feature of cancer cells that does not exist in normal cells. By further characterizing the biology of ecDNAs using their Spyglass platform, Boundless is generating a broad pipeline of ecDNA-directed therapies (ecDTx) to target gene amplified cancers.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com